Tag - PRTG

Developments

Portage relaunches independent subsidiary with Peter Molloy as CEO

Portage Biotech (NASDAQ:PRTG) has announced the relaunch of its wholly-owned adenosine subsidiary, Cyncado Therapeutics, as an independently managed company headed by Peter Molloy as CEO. The company reports that...

January 6, 2025

Markets

Cantor starts Portage Biotech at OW; PT $35

Cantor Fitzgerald launched coverage of Portage Biotech (NASDAQ:PRTG) with an “overweight” rating and $35 price target. The stock closed at $18.95 on Aug. 18. Portage Biotech is a clinical biopharmaceutical company...

August 19, 2021

Tag - PRTG

Portage relaunches independent subsidiary with Peter Molloy as CEO

Cantor starts Portage Biotech at OW; PT $35

General

More